Company intelligence / Profile preview
Alligator Bioscience AB
Lund, Swedenalligatorbioscience.se ↗
- Ownership
- Public · ATORX
- Employees
- ~46
- Development stage
- Other
01
Overview
Mitazalimab (lead asset) showed promising results in OPTIMIZE-1 Phase 2 trial for pancreatic cancer with 29.4% survival rate at 24 months, which is three times higher than chemotherapy alone. The company is preparing for Phase 3 initiation in H1 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-based pharmaceuticalsMonoclonal antibodiesBispecific antibodiesAgonistic mono- and bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Shanghai Henlius Biotech Inc.Aptevo Therapeutics Inc.MacroGenics Inc.Orion CorporationBiotheus Inc.Abclon Inc.BioArctic AB
04
Financials
- Market cap
- $54.8K
- Total revenue
- $52.1K
- Enterprise value
- $-1.3M
Beyond the preview
Go deeper on Alligator Bioscience AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alligator Bioscience AB.